BCPS Learning Hub

🎯 Exam Psychology

Mental strategies, pacing drills, and high-yield exam mindset training

🧠 Exam Skills & Strategy

Optimize your BCPS exam performance with cognitive strategies, stem dissection, timing mastery, and interactive drills

⏱️ Timing Mastery Calculator

Plan your exam pacing strategy

Total exam questions

Total exam time (min)

Target skip buffer (%)

⏱️ Time per question1:21

🔖 Check-in at Q50—

🔖 Check-in at Q100—

🎯 Reserve for review (min)—

Strategy: If behind pace at Q50 checkpoint, increase speed on straightforward questions. Never spend >3 min on any single question — mark and return.

🔬 Question Stem Anatomy

How to dissect a BCPS question in 3 steps

1️⃣Read the LAST sentence first. The actual question is always there. This primes your brain to read the stem for the RIGHT information instead of everything.

2️⃣Extract the 3 key facts while reading: Patient profile (age/organ function), Current medications, The clinical problem. These 3 facts drive 90% of BCPS answer choices.

3️⃣Eliminate before selecting. Remove clearly wrong options first. If 2 choices remain and you are unsure, choose the more specific or guideline-supported option — BCPS tests guidelines, not instinct.

🚩Red flag words: "EXCEPT" / "NOT" / "MOST appropriate" / "LEAST likely" — circle these. One mismatch = wrong answer even if you know the content.

🎯Distractor patterns: BCPS loves plausible-sounding options with wrong doses, wrong indications, or missing contraindications. The "almost right" answer is always the hardest distractor.

🧩 Cognitive Bias Training

Recognize the errors that cause exam failure

🎭Anchoring Bias: Your first impression anchors you to one diagnosis/drug. Always re-read the question after choosing — does your answer actually answer what was asked?

🔁Availability Heuristic: Choosing the condition you just studied feels right but may not match the question. Rely on the specific patient facts, not recent study material.

✔️Premature Closure: Stop evaluating too early. Even if Option A sounds right, read ALL four options — Option D may be more specific or more complete.

📐Base Rate Neglect: For BCPS, prevalence matters. If a question involves a patient on multiple medications, the most common drug interaction is usually the right answer, not the rare one.

🔄Changing Answers: Research shows: change answers only when you have a CLEAR reason. A vague "feeling" is not a reason. First instincts are correct ~60% of the time.

🏋️ Rapid-Fire Drill: Stem Strategy

Practice applying stem-dissection technique

Question 1 of 6 | Score: 0/0

🧘 Pre-Exam Mental Optimization

Performance psychology for exam day

😴Sleep is non-negotiable. REM sleep consolidates pharmacology memory into retrieval pathways. Pulling an all-nighter costs 20–30% cognitive performance — not worth it for any amount of last-minute review.

🥗Glucose management: Complex carbs + protein before the exam sustains glucose more reliably than simple sugars. Avoid caffeine overdose — mild anxiety amplification is useful; panic is not.

🌬️4-7-8 Breathing: When stuck on a hard question — inhale 4 sec, hold 7, exhale 8. This activates parasympathetic response, lowers cortisol, restores prefrontal function within 60 seconds.

🎯Confidence calibration: Don't aim for certainty on every question. You need ~73% correct to pass. Some questions are experimental and uncounted. Release the need to be perfect on every stem.

🔋Energy scheduling: Peak cognitive function typically occurs 2-3 hours after waking. If possible, schedule review/practice at your exam time to train your circadian rhythm.

📋 BCPS Blueprint Strategy Map

Maximize points per study hour

📊Area 1 (36%): Highest yield per hour. Focus on: acute care cardiology, ID, critical care PK. These topics overlap frequently — one drug (vancomycin) may appear in 3-4 different contexts.

📊Area 2 (36%): Biostatistics is high-yield per study hour — mastering 8 statistical concepts covers ~10-15 questions. Drug interactions and pharmacogenomics are high-frequency topics.

📊Area 3 (28%): Regulatory questions are rules-based — memorizable and reliable. DEA schedules, REMS programs, ISMP lists, and FDA approval pathways are excellent low-effort, high-return topics.

⚖️Time allocation model: If studying 200 total hours: ~72 hrs Area 1 (36%), ~72 hrs Area 2, ~56 hrs Area 3. Within each area, weight topics by: frequency in BCPS prep materials + personal weakness.

🔄Spaced repetition beats massed practice for pharmacology memory. 5 exposures over 5 weeks > 5 exposures in 1 day. Use the flashcard SR system in this hub starting 6-8 weeks before the exam.

📝 Full Case Walkthrough: Apply Every Strategy

Step-by-step stem dissection with think-aloud commentary

QUESTION STEM:
A 67-year-old man (78 kg, CrCl 28 mL/min) with MRSA bacteremia is started on vancomycin. Target AUC/MIC is 400–600 mg·h/L. The isolate's vancomycin MIC is 1 mcg/mL. Steady-state AUC is estimated at 330 mg·h/L using a 2-point PK method after the 3rd dose of 1250 mg q12h. Which adjustment is most appropriate?

A. Increase dose to 1500 mg q12h
B. Increase dose to 1750 mg q12h
C. Increase dose to 1500 mg q12h AND extend interval to q18h
D. Change to daptomycin 8 mg/kg q24h — vancomycin AUC subtherapeutic

Step 1 — Read last sentence first: "Which adjustment is most appropriate?" → I need to fix a subtherapeutic vancomycin AUC. The question is about dose optimization.

Step 2 — Extract 3 key facts: Patient: 78 kg, CrCl 28 (reduced renal clearance → longer t½ → accumulation risk). Drug: vancomycin. Problem: AUC 330, target 400-600. The AUC is LOW but not catastrophically low — I need a proportional increase.

Step 3 — Eliminate: Option D (switch to daptomycin) is premature — AUC is 330 and target is 400-600; a dose increase should be tried first before switching agents, per ASHP/SIDP/SCCM guidelines. Eliminate D. Between A, B, C: AUC is ~78% of target (330/430 midpoint). Need ~30% AUC increase. AUC is proportional to dose: 30% ↑dose = 30% ↑AUC. Current dose 1250 × 1.30 = 1625 mg ≈ 1750 mg. Option B. With CrCl 28, extending interval makes pharmacokinetic sense but the AUC is a total measure — interval affects trough/peak distribution but not total AUC meaningfully for a well-spaced regimen. Answer: B — 1750 mg q12h.

Cognitive bias check: Did I anchor on "low renal function = extend interval"? That anchoring bias could push toward C. Remember: AUC/MIC monitoring focuses on total drug exposure (AUC) — interval adjustment changes peak/trough but not AUC unless clearance changes. A proportional dose increase is the right move.

📐 BPS Exam Design Methodology

How question writers think — and how to reverse-engineer it

🏗️ How BPS Constructs Board Questions

The item-writing philosophy behind every BCPS question

📊Bloom's Taxonomy Applied: BPS deliberately tests at Level 3+ (Application) and Level 4 (Analysis), NOT recall. A question is never just "What is the dose of X?" — it is always "Given this patient with these constraints, which option is most appropriate?" Memorizing facts is necessary but not sufficient.

🔬Clinical Vignette Format: Every stem is a patient scenario for a reason — it tests your ability to integrate pharmacotherapy into real clinical decision-making. The patient's renal function, weight, allergies, and comorbidities are NEVER distractors — they are always clinically relevant to the correct answer.

🎯Best Answer vs. Correct Answer: BPS uses "most appropriate" because multiple options may be technically correct. The key discriminator is: which answer reflects current guideline recommendations, is safest for this specific patient, and is most evidence-based? This is why you must know WHY the guideline recommends what it does.

⚖️Distractor Construction: BPS item writers deliberately create plausible wrong answers that are: (1) correct for a different patient population, (2) outdated guideline recommendations, (3) correct drugs for the wrong indication, (4) correct indication but wrong dose/interval. Recognizing these distractor types is a skill.

📋Content Blueprint: Area 1 (Patient Care Specialty) = 36%, Area 2 (Therapeutics & Management) = 36%, Area 3 (Systems & Evidence) = 28%. Within those domains, questions are weighted by clinical prevalence and patient safety impact — high-alert medications, monitoring parameters, and drug interactions appear disproportionately often.

🔄Angoff Standard Setting: Pass scores are set by a panel of expert pharmacists estimating what percentage of minimally competent candidates would answer each question correctly. This means: some questions are DESIGNED to be answered by ~55% of candidates, others by 85%. Don't let a hard question demoralize you — it's likely designed to separate the top 15%.

🧩 The 4 Distractor Archetypes

Pattern-recognize wrong answers before reading options

Type 1: Wrong Population

Correct drug/dose but wrong patient. Example: metformin is the right first-line T2DM drug — but NOT if the patient has eGFR <30. The distractor presents metformin; the correct answer is an alternative like SGLT2i or GLP-1. Recognition signal: patient has an organ dysfunction, pregnancy, or contraindication clue in the stem.

Type 2: Outdated Guidelines

Former standard-of-care that guidelines have superseded. Example: carbamazepine/phenytoin for trigeminal neuralgia (still valid) vs. older antibiotics replaced by newer evidence. BPS tests current guidelines — if you learned something 5+ years ago without updating, this is your trap.

Type 3: Right Drug, Wrong Parameter

Correct drug choice, but the dose, interval, route, or monitoring threshold is wrong. Example: vancomycin AUC target 400-600 (correct), but the distractor says 200-300 or offers "trough-only monitoring" (outdated). Requires you to know not just WHAT but at exactly WHAT NUMBER.

Type 4: Plausible Alternative That Requires Additional Step

The option is a valid therapy but not the most appropriate FIRST step. Example: switching anticoagulants when the patient is subtherapeutic — the correct answer is checking adherence and dose-adjusting first, not switching agents. BPS tests "appropriate sequence" not just "valid options."

📈 BPS Biostatistics: The Mental Model

The specific framework BPS uses to test statistics and EBM

🔑The BPS Stats Question Template: "A trial reports [RR/OR/ARR/NNT] of [X] with 95% CI [Y-Z]. Which interpretation is correct?" — BPS tests 3 things simultaneously: (1) Can you interpret the statistic? (2) Does the CI cross the null? (3) Is this clinically meaningful? You must answer all three to select the right option.

🚩The CI Null-Crossing Rule: For ratios (RR, OR, HR), statistical significance = CI does NOT cross 1.0. For differences (ARR, MD), CI does NOT cross 0. This is testable without a p-value. BPS will give you a CI and test whether you know the null without saying "is p < 0.05?"

📉RRR vs. ARR Trap: BPS commonly presents RRR (always larger, more impressive-sounding) to test if you can identify the misleading framing. RRR = 40% sounds great; ARR = 0.5%, NNT = 200 sounds less impressive. The correct answer usually asks which measure best reflects clinical impact — always ARR or NNT.

🎓Study Design Hierarchy on BCPS: RCT > Cohort > Case-Control > Cross-sectional > Case series. BPS tests: (1) Which study design can prove causation? (Only RCT), (2) Which is best for rare diseases? (Case-control), (3) Which cannot calculate incidence? (Case-control — use OR not RR). These distinctions are high-yield.

⚡ The 60-Second Biostat Framework (memorize this)

1. What study design? → determines what statistic is valid
2. What is the point estimate? → RR, OR, ARR, NNT, HR
3. Does the CI cross the null? → crosses = not significant
4. Is the effect clinically meaningful? → ARR and NNT, not RRR
5. Is there a bias? → selection, information, confounding, or lead-time
Answer the question through these 5 lenses. BPS questions that test statistics almost always require step 4 or 5 to eliminate the wrong answer.

🔍 Advanced Stem Dissection: BPS-Specific Signals

Keywords that change everything — and what they signal

🔴

Organ function clues

"CrCl 25 mL/min" → renal adjustment needed · "Child-Pugh C" → hepatic dosing · "BMI 48" → obesity PK changes · "dialysis 3x/week" → drug removed by HD?

🟡

Superlative qualifiers

"MOST appropriate" = best per guidelines, not just valid · "LEAST likely" = flips your answer logic · "INITIAL" = first-line only · "NEXT" = sequence matters, not end goal

🟢

Current therapy clues

Drug list in stem = look for interaction, contraindication, or redundancy · DOAC + strong CYP3A4 inhibitor = dose adjustment or alternative needed · ACEi + ARB = avoid combination (dual RAAS blockade)

🔵

Lab result signals

Elevated SCr = nephrotoxicity or dose reduction · Low platelet <50k → anticoagulation caution · INR 1.8 on warfarin = subtherapeutic → adherence vs. interaction · K+ 5.8 on RAAS drug → hold or reduce

🟣

Demographic flags

Age >65 = Beers Criteria awareness · Pregnancy = teratogenicity and safety classes · Pediatric = weight-based dosing · Asian patient + carbamazepine = HLA-B*15:02 SJS risk

⚡ High-Yield BPS Answer Selection Rules

Decision rules that apply to 80% of BCPS questions

Rule 1 — Guideline Supremacy: If the stem gives you a published guideline context (ACC/AHA, ASHP, IDSA, CHEST, etc.), the answer is whatever the current guideline says, even if clinical judgment might differ. BPS tests adherence to evidence-based guidelines.

Rule 2 — Sequence Before Switch: When a drug isn't working, optimize before switching. Max dose before adding adjunct. Check adherence before changing class. This is the "stepwise therapy" philosophy BPS consistently tests.

Rule 3 — Safety First in Ambiguity: When two options are both efficacious, the safer option (fewer side effects, established monitoring parameters, narrower therapeutic index awareness) is usually correct. BPS asks "most appropriate" — that incorporates safety.

Rule 4 — The Specific Beats the General: "Recommend vancomycin for MRSA" is less specific than "Recommend vancomycin AUC/MIC-guided dosing targeting 400-600 for MRSA bacteremia." BPS expects specificity. The more specific, quantitatively accurate answer is typically correct.

Rule 5 — Numbers are Testable, Concepts are Eliminators: Knowing the exact numerical thresholds (HbA1c <7%, LDL goal <70 mg/dL for very high risk, vancomycin AUC 400-600, anticoagulation INR 2-3) separates passing from failing. BPS uses exact numbers in distractors — close but wrong.

🧠 The Master Framework: How Elite Scorers Think

The mental model of candidates who score 85%+

Phase 1: Stem Triage (10 seconds)

Read last sentence → identify question type (dosing? monitoring? drug interaction? EBM?) → activate the right knowledge module before reading the full stem.

Phase 2: Constraint Extraction (20 seconds)

Read stem for constraints: organ function, age, allergies, current meds, labs. These constraints eliminate at least 1-2 options before you even read them. Build a mental "required characteristics" list.

Phase 3: Option Evaluation (30 seconds)

Apply constraints to eliminate. Then apply the 5 Rules. For remaining options: which is more evidence-based? More specific? More current? More guideline-aligned? Select it.

Phase 4: Verification (5 seconds)

Re-read the question stem's last sentence. Does your answer actually answer WHAT WAS ASKED? This catches anchoring errors. If yes — commit, move on. Zero second-guessing without new information.

📋 The 7 BPS Question Types (Complete Field Guide)

Know the type → apply the right strategy immediately

80% of BPS questions test tacit (application) knowledge — not memorized facts. 90% test patient care & evidence translation.

1️⃣ Background Questions

What: Tests basic/explicit knowledge (facts, definitions).

Strategy: Pure memorization. These are fast — don't overthink them.

2️⃣ Foreground Questions

What: Applies facts to a real clinical situation — requires tacit knowledge.

Strategy: Go deeper than recall — ask "why does this matter for THIS patient?"

3️⃣ Negative Questions (NOT / EXCEPT / NEVER)

Strategy: Convert to True/False. Evaluate each option as a T/F statement. The FALSE statement = correct answer.

Example: "Which is NOT a risk factor for diabetes?" → Evaluate each option as "X IS a risk factor" — the FALSE one wins. NSAID use → False → correct answer.

4️⃣ Conjunction Questions (and / but / for / nor / yet)

What: Two equally important components connected by a conjunction.

Strategy: Treat each part as its own question. If ANY part is wrong → the entire answer is wrong → eliminate it.

5️⃣ Two-Step Questions

What: 2-component question where Part 2 depends on Part 1 answer.

Strategy: Solve Part 1 first, THEN solve Part 2 using that answer. Both components must be correct — one wrong = all wrong.

6️⃣ Bait & Switch Questions

What: Leads you in one direction, then pivots to ask something different.

Strategy: Always identify the ACTUAL question — usually the last sentence. Don't answer what you THINK they're asking. Answer what they actually ask.

7️⃣ Case-Based Questions (Most Complex — See Next Card)

What: Full clinical scenario with PMH, labs, meds, exam findings.

Strategy: Read ENTIRE case in order. Build pattern of association. Do NOT jump to question first.

Universal Tips: Longer answers are often correct (writers add qualifying language). Eliminate answers with extreme wording (always/every/must/never/only) — medicine is rarely one-size-fits-all. If you must qualify your answer, it is likely wrong. Grammatical fit between question and answer can be a clue. Never assume more information than provided.

🏥 Mastering Case-Based Questions: The 6-Step Method

The most complex and highest-yield question type on BPS exams

Case-based questions test Bloom's Level 3-4: analysis and application. Multiple options may seem "correct" — only ONE is BEST for this specific patient.

Work in order. Don't jump to the question. Clinical cases build chronologically — the pattern of association directs you to the answer. Jumping ahead breaks the narrative logic.

Look for the pattern. Don't memorize all details — identify the association between them. What does this constellation of findings point to?

Judge the information. Don't just notice labs and meds — evaluate them. Ask: Does this patient have an indication for that drug? Are these labs expected from the PMH, or do they signal a new problem? Could the current treatment be causing the new symptoms?

Don't presume. Do not assume a cause unless stated. The question may be testing your ability to think outside the typical presentation. If you're thinking "I'd ask for more information" — you're off track. All needed details are in the stem.

Consider the "how." Go beyond guidelines — think about mechanism. How does this drug work? What secondary consequences (benefits or harms) does that create? This is what separates foreground from background mastery.

Formulate before reading options. Mentally commit to an answer before seeing the choices. This prevents distractor anchoring — being seduced by a plausible-but-wrong option. Then: if options match your gut → you're probably right. Tiebreaker: mortality/QoL benefit wins.

Panic Protocol: Remember a core concept is being tested — not a trick. Trust your first instinct. Eliminate 1-2 options: 25% guess → 50-75% odds. Never leave blank. Take a breath, reset, attack it like a clinical consult.

Lab Interpretation is Mandatory: You WILL be tested on basic lab interpretation. Know: CMP, CBC, TSH, lipid panel, coagulation studies. Be comfortable identifying when a lab is unexpected given the PMH — that's often the pivot point of the question.

🚩 Red Flag Medications & Killer Foils

High-risk drugs with predictable question patterns + look-alike diagnoses that demand different treatment

When you see a Red Flag drug in a question stem — stop. There are only a few directions the question can go, and they always test the same classic teaching concept.

🚨 Red Flag Medications (Spot These — Know The Issue)

Amiodarone — Extreme half-life (weeks–months). Interactions with Digoxin & Warfarin (↑ levels — reduce doses). Classic toxicities: Pulmonary fibrosis, Hepatotoxicity, QT prolongation, Ocular (corneal microdeposits, vision changes), Hypo/Hyperthyroidism, Blue-gray skin discoloration. Questions often test rate/timing of administration or toxicity monitoring.

Warfarin — Multiple drug & food interactions (CYP2C9). Narrow therapeutic index. INR monitoring. Reversal agents (Vitamin K, FFP, 4-factor PCC). Hold before surgery.

Digoxin — Narrow therapeutic index. Toxicity: bradycardia, AV block, visual changes (yellow-green halos), nausea. Levels affected by amiodarone, quinidine, verapamil. Hypokalemia worsens toxicity.

Lithium — Narrow TI. Toxicity with dehydration, NSAIDs, ACE inhibitors, thiazides. Monitor renal function. Tremor → toxicity sign.

Aminoglycosides / Vancomycin — Nephrotoxicity + ototoxicity. AUC-guided dosing for vancomycin. Peak/trough or AUC/MIC targets. Adjust for renal function.

Methotrexate — Hepatotoxicity, myelosuppression, mucositis. Leucovorin rescue. Hold with renal impairment. Drug interaction with NSAIDs (↑ MTX levels).

Clozapine — Agranulocytosis (mandatory ANC monitoring via REMS). Also: metabolic syndrome, myocarditis, seizures. Most effective antipsychotic for treatment-resistant schizophrenia.

⚔️ Killer Foils (Similar Presentation → Different Treatment)

A "killer foil" = two diagnoses that look identical in the stem, but require different treatments. Knowing the single distinguishing feature is the entire question.

Mononucleosis (EBV) vs. Strep Pharyngitis (GABHS)
Both: sore throat + fever + lymphadenopathy. Key differentiator: Mono = posterior cervical lymphadenopathy + splenomegaly (LUQ pain). Strep = anterior chain. Treatment: Mono → supportive care ONLY (no antibiotics). Strep → antibiotic (penicillin/amoxicillin). Critical trap: Amoxicillin in mono causes a diffuse maculopapular rash — NOT an allergic reaction. No epinephrine/diphenhydramine needed.

Serotonin Syndrome vs. NMS (Neuroleptic Malignant Syndrome)
Both: hyperthermia + altered mental status + muscle rigidity. Key differentiator: SS = clonus/hyperreflexia + rapid onset (hours) + serotonergic drug. NMS = lead-pipe rigidity + slow onset (days) + dopamine antagonist. Treatment: SS → cyproheptadine + benzodiazepines. NMS → bromocriptine/dantrolene + supportive care.

HOCM vs. Aortic Stenosis
Both: systolic murmur + exertional syncope. Key differentiator: HOCM = murmur INCREASES with Valsalva/standing (↓ preload worsens obstruction). AS = murmur decreases with Valsalva. Treatment: HOCM → beta-blockers/CCBs, avoid vasodilators. AS → surgical/TAVR.

HIT (Heparin-Induced Thrombocytopenia) vs. Non-Immune Thrombocytopenia
Both: platelet drop on heparin. Key differentiator: HIT = 50% platelet drop 5-10 days after heparin start + thrombosis risk. 4Ts score ≥4 → high suspicion. Treatment: STOP heparin, start non-heparin anticoagulant (argatroban, bivalirudin, fondaparinux). Do NOT just stop heparin — anticoagulation is mandatory.

Type 1 vs. Type 2 MI
Both: troponin elevation. Key differentiator: Type 1 = plaque rupture/thrombosis. Type 2 = supply/demand mismatch (sepsis, severe anemia, tachyarrhythmia). Treatment differs: Type 1 → ACS protocol (antiplatelet, anticoagulation, cath). Type 2 → treat the underlying cause. Giving dual antiplatelet for a Type 2 MI is wrong.

Killer Foil Mindset: When a clinical scenario doesn't quite fit the expected disease, look for the one differentiating detail. The question is testing whether you know the single distinguishing feature. Train yourself to identify what DOESN'T fit — that's where the answer lives.

📊 Biostatistics & EBM: Why It Can Make or Break Your Exam

Without proper preparation here, you will not pass your BPS exam

Since 1992, EBM has been integrated into board exams. The BPS tests whether you can critically evaluate evidence — not just recall guidelines. This is the most commonly under-prepared domain.

The 3 Pillars of EBM (Equally Weighted)

📚

Best Available Evidence

RCTs, systematic reviews, meta-analyses

🩺

Clinical Expertise

Specialist knowledge, judgment, experience

👤

Patient-Specific Factors

Values, preferences, comorbidities

No single pillar dominates. Questions test integration of all three.

Core Biostat Concepts Tested

Sensitivity vs. Specificity: SnNout (Sensitive test, Negative rules OUT). SpPin (Specific test, Positive rules IN). Sensitivity = true positives/(TP+FN). Specificity = true negatives/(TN+FP).

NNT & NNH: NNT = 1/ARR. Always prefer ARR over RRR — RRR can make small effects look large. NNT of 20 means 20 patients must be treated to prevent 1 event.

Confidence Intervals: If 95% CI crosses 1.0 (for RR/OR) or crosses 0 (for difference in means) → result is NOT statistically significant. CI crossing null = no demonstrated effect. This is the most common biostat trap on boards.

P-value: p<0.05 = statistically significant (5% probability this result occurred by chance). Does NOT mean clinically significant. A tiny difference can be statistically significant with a large enough sample size.

Study Design Hierarchy: Systematic review/meta-analysis > RCT > Cohort > Case-control > Cross-sectional > Case report. Only RCTs can establish causality. Observational studies show association, not causation.

Intention-to-Treat (ITT) vs. Per-Protocol: ITT = analyzes all randomized patients regardless of adherence → preserves randomization → gold standard for efficacy claims. Per-protocol excludes non-adherent patients → overestimates efficacy. If a study uses per-protocol, its efficacy data may be inflated.

Blinding: Single-blind = patient unaware. Double-blind = patient AND investigator unaware. Triple-blind = patient, investigator, AND data analysts unaware. Lack of blinding = performance bias + detection bias.

Type I vs. Type II Error: Type I (α) = false positive — rejected null when true. Type II (β) = false negative — failed to reject null when false. Power = 1-β. Underpowered studies miss real effects.

The BPS Biostat Mindset: Every clinical question on this exam is anchored to evidence. When evaluating a trial, ask: What was the study design? Was it ITT? What did the CI include? Was the difference clinically meaningful, or just statistically significant? Is the study population similar to my patient? Answering these in sequence reveals the correct answer even when you don't recognize the specific trial.

Historical Warning: The "Back to Sleep" campaign. For decades, prone sleeping was recommended for infants despite evidence that it increased SIDS risk — and it persisted until 1994. Expert opinion without evidence costs lives. This is why EBM exists — and why the BPS tests it heavily.

📖 Study Guide

ACCP Updates in Therapeutics — 22 high-yield chapters

449

Practice Questions

206

Flashcards

Drug Profiles

492

Glossary Terms

Acute Care CardiologyVolume 1

Covers ACS, heart failure decompensation, arrhythmias, and cardiogenic shock management.

ACS Management

Therapy	STEMI	NSTEMI/UA
Aspirin	162-325mg load, then 81mg daily	Same
P2Y12 inhibitor	Ticagrelor 180mg load preferred	Ticagrelor or clopidogrel
Anticoagulation	UFH or bivalirudin (PCI)	UFH, enoxaparin, or fondaparinux
Reperfusion	PCI <90min (door-to-balloon)	Risk-stratify; early invasive if high-risk

Acute HF Decompensation

Profile	Tx Strategy
Warm & Wet	IV diuresis (furosemide 2.5× oral dose)
Cold & Wet	Vasopressors + diuresis
Cold & Dry	Cautious fluid challenge, then vasopressors

Clinical Pearl: BNP >500 supports HF diagnosis; <100 makes HF unlikely. NT-proBNP cutoffs are age-adjusted (450/900/1800 pg/mL for <50/50-75/>75 years).

Cross-Volume Link: See Nephrology (Vol 2) for cardiorenal syndrome and diuretic resistance strategies.

Chronic Care CardiologyVolume 1

Stable CAD, chronic HFrEF/HFpEF, hypertension, and dyslipidemia management.

HFrEF Pillars (Mortality Benefit)

Drug Class	Examples	Target Dose
ACEi/ARB or ARNI	Sacubitril/valsartan (ARNI preferred)	Sacubitril/val 97/103mg BID
Beta-blocker	Carvedilol, metoprolol succinate, bisoprolol	Max tolerated dose
MRA	Spironolactone, eplerenone	25-50mg daily
SGLT2i	Dapagliflozin, empagliflozin	Standard dose

HTN Goals (ACC/AHA 2017)

General: <130/80 mmHg
Diabetes/CKD: <130/80 mmHg
Age ≥65: <130 mmHg SBP

Statin Intensity

Intensity	Agents	LDL Reduction
High	Atorvastatin 40-80mg, Rosuvastatin 20-40mg	≥50%
Moderate	Atorvastatin 10-20mg, Rosuvastatin 5-10mg, Simvastatin 20-40mg	30-49%
Low	Simvastatin 10mg, Pravastatin 10-20mg	<30%

Clinical Pearl: ARNI (sacubitril/valsartan) is preferred over ACEi/ARB in HFrEF patients who can tolerate it. Requires 36-hour washout from ACEi before switching to prevent angioedema.

AnticoagulationVolume 1

VTE prevention, treatment, and special populations. AFib stroke prevention. Reversal agents.

DOAC Dosing in Non-valvular AFib

DOAC	Standard Dose	Dose Reduction Criteria
Apixaban	5mg BID	2.5mg BID if ≥2 of: age ≥80, wt ≤60kg, SCr ≥1.5
Rivaroxaban	20mg daily with dinner	15mg daily if CrCl 15-50
Dabigatran	150mg BID	75mg BID if CrCl 15-30
Edoxaban	60mg daily	30mg daily if CrCl 15-50, wt ≤60kg, or P-gp inhibitor

CHA₂DS₂-VASc Scoring

CHF(1), HTN(1), Age≥75(2), DM(1), Stroke/TIA(2), Vascular disease(1), Age 65-74(1), Sex category female(1)

Anticoagulate: men ≥2, women ≥3. Consider: men =1, women =2.

Reversal Agents

Agent	Reverses	Dose
Idarucizumab (Praxbind)	Dabigatran	5g IV (two 2.5g doses)
Andexanet alfa (Andexxa)	Factor Xa inhibitors	Low/high dose based on last dose timing
4F-PCC (Kcentra)	Warfarin, rivaroxaban (off-label)	25-50 units/kg based on INR
Vitamin K	Warfarin	2.5-10mg PO/IV

Cross-Volume Link: See Nephrology (Vol 2) for DOAC dosing adjustments in CKD/ESRD patients.

Infectious Diseases IVolume 1

Community-acquired infections: pneumonia, UTI, skin/soft tissue infections, and sepsis management.

CAP Treatment (ATS/IDSA 2019)

Setting	No Comorbidities	Comorbidities / Risk Factors
Outpatient	Amoxicillin 1g TID OR Doxycycline 100mg BID	Amox-clav + macrolide OR respiratory FQ
Inpatient (non-ICU)	Beta-lactam + macrolide	Beta-lactam + macrolide OR respiratory FQ
ICU	Beta-lactam + azithromycin OR beta-lactam + FQ	Add anti-Pseudomonal if risk factors

UTI Treatment

Type	First-line	Duration
Uncomplicated cystitis (women)	Nitrofurantoin 100mg BID or TMP-SMX DS BID	5 days (nitro) or 3 days (TMP-SMX)
Complicated UTI/pyelonephritis	Fluoroquinolone or broad-spectrum beta-lactam	5-14 days based on severity
Catheter-associated UTI	Based on culture; remove catheter if possible	7 days if prompt response

Sepsis-3 Definitions

Sepsis: Life-threatening organ dysfunction (SOFA score increase ≥2) from presumed infection.

Septic shock: Sepsis + vasopressor requirement + lactate >2 mmol/L despite adequate fluid resuscitation.

Sepsis 1-Hour Bundle

Measure lactate (re-measure if >2)
Blood cultures before antibiotics
Broad-spectrum antibiotics within 1 hour
30mL/kg IV crystalloid for hypotension or lactate ≥4
Vasopressors for MAP <65 mmHg

Clinical Pearl: Procalcitonin guidance helps de-escalate antibiotics in CAP. PCT <0.25 ng/mL = consider stopping; PCT decrease >80% from peak = de-escalate.

Infectious Diseases IIVolume 1

Hospital-acquired infections, resistant organisms, fungal infections, HIV, TB, and antiviral therapy.

Hospital-Acquired Pneumonia (HAP/VAP)

Risk Factor	Empiric Coverage Needed
MRSA risk factors (prior MRSA, IV antibiotics in 90 days, structural lung disease)	Add vancomycin or linezolid
Pseudomonas risk (structural lung, prior Pseudomonas, recent antibiotics)	Anti-pseudomonal beta-lactam (pip-tazo, cefepime, meropenem)
No risk factors	Cefepime, pip-tazo, or levofloxacin

MRSA Treatment Options

Indication	Preferred Agent
Bacteremia / Endocarditis	Vancomycin IV (AUC-guided) or daptomycin
Pneumonia	Vancomycin or linezolid (linezolid preferred for VAP)
SSTI (uncomplicated)	TMP-SMX DS BID or doxycycline 100mg BID x 5-7 days

C. difficile Treatment

Severity	Treatment
Non-severe (WBC <15k, SCr <1.5)	Vancomycin PO 125mg QID x 10 days OR fidaxomicin 200mg BID x 10 days
Severe (WBC ≥15k or SCr ≥1.5)	Vancomycin PO 125mg QID x 10 days
Fulminant	Vanco PO 500mg QID + metronidazole IV 500mg q8h ± surgery consult
Recurrent (1st)	Fidaxomicin preferred; Bezlotoxumab for high recurrence risk

HIV Key Concepts

ART initiation: recommended for ALL HIV+ patients regardless of CD4 count
Goal: HIV RNA undetectable (<50 copies/mL)
PCP prophylaxis: TMP-SMX 1 SS daily when CD4 <200
MAI prophylaxis: azithromycin 1200mg weekly when CD4 <50

Clinical Pearl: Linezolid for MRSA pneumonia provides both MRSA coverage and lung penetration. Monitor for serotonin syndrome with linezolid + serotonergic drugs (SSRIs, TCAs).

Critical CareVolume 1

Mechanical ventilation, vasopressors, sedation/analgesia, and ICU pharmacotherapy.

Vasopressor Hierarchy (Septic Shock)

Agent	Role	Key Points
Norepinephrine	First-line	α1>β1; preferred in septic shock
Vasopressin	Add-on (second-line)	0.03-0.04 units/min; steroid-sparing effect
Epinephrine	Second/third-line	Causes hyperglycemia, lactic acidosis
Dopamine	Alternative first-line	More arrhythmias vs NE; avoid in tachycardia
Phenylephrine	Specific indications	Pure α1; avoid in low CO states

Lung-Protective Ventilation (ARDSNet)

Tidal volume: 6 mL/kg IBW (4-8 range)
Plateau pressure: ≤30 cmH₂O
PEEP: per FiO₂/PEEP table
Target SpO₂ 88-95%, PaO₂ 55-80 mmHg

Sedation (PADIS Guidelines)

A-F Bundle: Assess/Treat pain, Both SAT+SBT, Choice of analgesia-first sedation, Delirium monitoring, Early mobility, Family engagement.

Preferred: Propofol or dexmedetomidine over benzodiazepines for sedation. Target RASS -1 to 0 (light sedation).

Fluids, Electrolytes & NutritionVolume 1

IV fluid selection, electrolyte management, and nutritional support in hospitalized patients.

IV Fluid Comparison

Fluid	Na (mEq/L)	Key Points
Normal Saline (0.9%)	154	Hyperchloremic metabolic acidosis with large volumes; preferred for hyponatremia, hypochloremia
Lactated Ringers	130	More physiologic; preferred for resuscitation (SMART, SALT-ED trials); avoid with hyperkalemia
D5W	0	Free water; used for hypernatremia correction; NOT for resuscitation
Albumin 5%	130-160	Colloid; used in SBP prophylaxis, hepatorenal syndrome, large-volume paracentesis

Electrolyte Disorders

Disorder	Treatment
Hyponatremia (symptomatic)	Hypertonic saline 3%; correct <8-10 mEq/L per 24h (risk of ODS if faster)
Hypernatremia	Free water replacement; correct <10-12 mEq/L per 24h
Hypokalemia	PO preferred; IV KCl for severe (<3.0); replace Mg simultaneously
Hypomagnesemia	IV MgSO4 for severe; refractory hypokalemia/hypocalcemia = check Mg
Hypophosphatemia	PO sodium/potassium phosphate for mild-moderate; IV Neutra-Phos for severe

Nutrition Support

Enteral nutrition (EN): Preferred over PN when GI tract functional; start within 24-48h in ICU
Parenteral nutrition (PN): Reserve for non-functional GI tract; monitor glucose, TGs, LFTs, electrolytes
Refeeding syndrome: Risk with severe malnutrition; characterized by hypophosphatemia, hypokalemia, hypomagnesemia within 72h of refeeding

Clinical Pearl: Balanced crystalloids (LR) are preferred over NS for most resuscitation. NS is still preferred for metabolic alkalosis, hyponatremia, and neurosurgical patients.

PsychiatryVolume 1

Depression, anxiety, bipolar disorder, schizophrenia, ADHD, and substance use disorder pharmacotherapy.

Antidepressant Selection

Drug Class	Examples	Key Considerations
SSRIs (first-line)	Sertraline, escitalopram, fluoxetine	Safe in most populations; QTc concern with citalopram (>40mg)
SNRIs	Venlafaxine, duloxetine, desvenlafaxine	Also for neuropathic pain, GAD, fibromyalgia
Bupropion	Bupropion SR/XL	No sexual side effects; aids smoking cessation; lowers seizure threshold; avoid in eating disorders
Mirtazapine	Mirtazapine 7.5-45mg	Sedating (especially at low doses); increases appetite; useful in elderly, insomnia
TCAs	Amitriptyline, nortriptyline	Anticholinergic; QTc prolongation; lethal in overdose; use cautiously in elderly (Beers)

Antipsychotics

Generation	Examples	Side Effects
First-generation (FGA/typical)	Haloperidol, chlorpromazine, fluphenazine	EPS, tardive dyskinesia, hyperprolactinemia; haloperidol preferred for acute agitation
Second-generation (SGA/atypical)	Risperidone, olanzapine, quetiapine, aripiprazole, clozapine	Metabolic syndrome (weight gain, dyslipidemia, DM); QTc; sedation
Clozapine	Reserved for treatment-resistant schizophrenia	Agranulocytosis (CBC monitoring required); myocarditis; seizures; most efficacious SGA

Bipolar Disorder Treatment

Acute mania: Lithium, valproate, or atypical antipsychotic (olanzapine, quetiapine)
Maintenance: Lithium (gold standard, suicide prevention), valproate, lamotrigine (for depressive episodes)
Lithium monitoring: Narrow TI (goal 0.6-1.2 mEq/L); renal function, thyroid, calcium at baseline and periodically

Substance Use Disorders

Substance	Pharmacotherapy
Alcohol use disorder	Naltrexone (first-line), acamprosate, disulfiram; thiamine for Wernicke prophylaxis
Opioid use disorder	Buprenorphine/naloxone (first-line outpatient), methadone (specialized clinic), naltrexone ER (Vivitrol)
Nicotine (smoking)	Varenicline (most effective), bupropion SR, NRT (patch, gum, lozenge)

Clinical Pearl: Serotonin syndrome (agitation, clonus, hyperthermia, diaphoresis) differs from NMS (bradykinesia, lead-pipe rigidity, hyperthermia) — key for drug interaction questions.

NeurologyVolume 1

Seizure management, ischemic stroke, Parkinson disease, pain pharmacotherapy, and headache treatment.

Seizure Pharmacotherapy

Drug	Use	Key Points
Levetiracetam (Keppra)	Broad-spectrum; focal and generalized	Renal adjustment; psychiatric side effects (irritability); no drug interactions
Valproate	Generalized epilepsy, absence, myoclonic	Teratogenic (neural tube defects); hepatotoxicity; inhibits CYP2C9; lamotrigine interactions
Lamotrigine	Focal, generalized, bipolar	Slow titration required (Stevens-Johnson risk if rapid); valproate doubles lamotrigine levels
Phenytoin/fosphenytoin	Acute seizures/status epilepticus IV	Narrow TI; zero-order kinetics; purple glove syndrome; hepatic enzyme inducer

Status Epilepticus Treatment (Stepwise)

Lorazepam IV 0.1mg/kg (or midazolam IM) → Fosphenytoin or valproate IV → Levetiracetam IV → Lacosamide IV → General anesthesia (propofol, midazolam, pentobarbital)

Ischemic Stroke Acute Management

IV tPA (alteplase): Within 3-4.5 hours of symptom onset; BP must be <185/110 before and 24h after
Mechanical thrombectomy: Within 24h if large vessel occlusion (LVO) and favorable imaging
Aspirin 325mg: Within 24-48h (not within 24h of tPA); dual antiplatelet (ASA+clopidogrel) for 21 days in minor stroke/TIA

Parkinson Disease Pharmacotherapy

Drug Class	Example	Role
Levodopa/carbidopa	Sinemet	Most effective; gold standard for motor symptoms
Dopamine agonists	Pramipexole, ropinirole, rotigotine	Monotherapy in younger patients; impulse control disorders
MAO-B inhibitors	Rasagiline, selegiline	Mild symptom control; serotonin syndrome with meperidine/SSRIs
COMT inhibitors	Entacapone	Add-on to levodopa; reduces wearing-off

Neuropathic Pain Management

First-line: gabapentinoids (gabapentin, pregabalin), SNRIs (duloxetine, venlafaxine), TCAs (nortriptyline)

Clinical Pearl: Contraindicated drugs in seizure patients: tramadol, bupropion, imipenem, and fluoroquinolones can lower the seizure threshold.

Sexual & Reproductive HealthVolume 1

Contraception, STI treatment, pregnancy pharmacotherapy considerations, and menopausal therapy.

Contraception Methods and Drug Interactions

Method	Failure Rate (typical use)	Key Considerations
Combined oral contraceptives (COCs)	7%	Enzyme inducers (rifampin, carbamazepine) reduce efficacy; absolute CI: migraine with aura + smoking + age>35
Progestin-only pill (POP)	7-9%	Option when estrogen contraindicated (breastfeeding, VTE history, HTN)
LNG-IUD (Mirena)	<1%	Effective 5-7 years; reduces menstrual bleeding
Copper IUD	<1%	Non-hormonal; also used for emergency contraception within 5 days
Etonogestrel implant (Nexplanon)	<1%	3-year implant; most effective reversible contraception

STI Treatment (CDC 2021 Guidelines)

STI	First-line Treatment
Chlamydia	Doxycycline 100mg BID x 7 days (preferred over azithromycin 1g single dose)
Gonorrhea (uncomplicated)	Ceftriaxone 500mg IM single dose (1g if weight >150kg)
Syphilis (primary/secondary)	Benzathine penicillin G 2.4 million units IM single dose
Bacterial vaginosis	Metronidazole 500mg BID x 7 days or 0.75% vaginal gel
Trichomoniasis	Metronidazole 2g single dose (or 500mg BID x 7 days)

Pregnancy Drug Safety Categories (FDA Labeling)

Avoid in pregnancy: ACEi/ARBs (2nd/3rd trimester - renal dysgenesis), valproate (neural tube defects), warfarin (embryopathy), isotretinoin (teratogenic), tetracyclines, fluoroquinolones
Safe in pregnancy: Penicillins, cephalosporins, azithromycin, insulin, labetalol/nifedipine (HTN)
UFH preferred over LMWH: In pregnancy for anticoagulation near delivery (reversible)

Clinical Pearl: Emergency contraception: levonorgestrel (Plan B) within 72h; ulipristal (ella) within 120h; copper IUD most effective option within 5 days of unprotected intercourse.

PharmacokineticsVolume 2

Drug absorption, distribution, metabolism, elimination, and individualized dosing using PK/PD principles.

Key PK Equations

Parameter	Formula
Cockcroft-Gault (CrCl)	[(140-age) × IBW / (72 × SCr)] × 0.85 if female
Loading dose	LD = Vd × Cp_target / F
Maintenance dose	MD = CL × Css_avg × dosing interval
Half-life	t½ = 0.693 × Vd / CL
Time to steady-state	~4-5 half-lives

Vancomycin AUC-Guided Dosing (ASHP/IDSA 2020)

Target AUC/MIC 400-600 mg·h/L (MIC ≤1 mg/L)
Two-point Bayesian estimation preferred over trough-only
Initial dose: 15-20 mg/kg actual body weight q8-12h
Winter-Tozer for obese: IBW + 0.4(TBW-IBW)

PK/PD Targets by Drug Class

Class	Parameter	Target
Beta-lactams	%T>MIC	40-70% (bactericidal)
Aminoglycosides	Cmax/MIC	8-10× MIC
Fluoroquinolones	AUC/MIC	>125 (Gram-neg)
Vancomycin	AUC/MIC	400-600 mg·h/L

Cross-Volume Link: Applies to ID (Vol 1) antibiotic dosing and Nephrology (Vol 2) renal dose adjustments.

Endocrine & MetabolicVolume 2

Diabetes management, thyroid disorders, adrenal insufficiency, and osteoporosis.

Diabetes Drug Selection

Patient Characteristic	Preferred Agent(s)
ASCVD or high CV risk	GLP-1 RA (liraglutide, semaglutide) or SGLT2i
HF (HFrEF or HFpEF)	SGLT2i (dapagliflozin, empagliflozin)
CKD (albuminuria)	SGLT2i + finerenone; GLP-1 RA if eGFR allows
Weight loss needed	GLP-1 RA or SGLT2i
Hypoglycemia risk	Avoid sulfonylureas; prefer DPP-4i, GLP-1 RA, SGLT2i
Cost constraints	Metformin first; sulfonylureas as add-on

A1c Targets

Most adults: <7%
Older adults / limited life expectancy: <8% or <8.5%
Pregnancy: <6% (if achievable without hypoglycemia)

DKA vs HHS

	DKA	HHS
Glucose	Usually 250-600	Usually >600
pH	<7.3	Normal or mildly low
Ketones	Positive	Absent/trace
Osmolality	Variable	>320 mOsm/kg

NephrologyVolume 2

AKI, CKD management, electrolyte disorders, and renal replacement therapy considerations.

AKI KDIGO Staging

Stage	SCr Criteria	UO Criteria
1	1.5-1.9× baseline or ↑≥0.3mg/dL in 48h	<0.5 mL/kg/h for 6-12h
2	2.0-2.9× baseline	<0.5 mL/kg/h for ≥12h
3	3× baseline, SCr ≥4.0, or RRT initiation	<0.3 mL/kg/h for ≥24h or anuria ≥12h

CKD Drug Adjustments (High-Yield)

Drug	CrCl Threshold	Action
Metformin	<30 mL/min	Contraindicated
Dabigatran	<15 mL/min	Avoid
Rivaroxaban (AFib)	<15 mL/min	Avoid
Apixaban	ESRD on HD	5mg BID (or 2.5mg BID if ≥2 of 3 criteria)
SGLT2i	eGFR <20-25	Not for glycemic control (heart/renal benefits may persist)
Gabapentin	<60 mL/min	Dose reduce

Hyperkalemia Treatment Ladder

Calcium gluconate (membrane stabilization) → Insulin + dextrose → Sodium bicarbonate → Kayexalate or patiromer → Dialysis

Pulmonology & VaccinationsVolume 2

Asthma stepwise therapy, COPD management, and adult immunization schedule.

Asthma Stepwise Approach (NAEPP)

Step	Preferred
1 (Intermittent)	SABA PRN
2 (Mild persistent)	Low-dose ICS
3 (Moderate)	Low-dose ICS + LABA or medium-dose ICS
4	Medium-dose ICS + LABA
5	High-dose ICS + LABA ± tiotropium
6	Step 5 + oral corticosteroid

COPD GOLD Classification

mMRC/CAT symptoms + exacerbation history → Groups A/B (low risk) vs E (high risk)

Group A: SABA or SAMA PRN
Group B: LAMA or LABA (LAMA preferred, or LAMA+LABA if very symptomatic)
Group E: LAMA + LABA; add ICS if eos ≥300 or frequent exacerbations

Key Vaccinations (Adult)

Vaccine	Key Population
Influenza	All adults annually
COVID-19	All adults (updated annually)
RSV (Abrysvo/Mresvia)	Age ≥60 (shared decision-making)
Pneumococcal (PCV20 or PCV15+PPSV23)	Age ≥65 or immunocompromised
Shingrix (RZV)	Age ≥50; 2 doses 2-6 months apart
Tdap	Once, then Td booster q10y

BiostatisticsVolume 2

Statistical concepts, measures of association, hypothesis testing, and interpreting clinical trial data for BCPS.

Key Statistical Measures

Measure	Formula / Definition
Sensitivity	TP / (TP + FN) — rules OUT if negative (SnNout)
Specificity	TN / (TN + FP) — rules IN if positive (SpPin)
PPV	TP / (TP + FP) — depends on prevalence
NPV	TN / (TN + FN) — depends on prevalence
NNT	1 / ARR; lower is better
NNH	1 / ARI; higher is safer
ARR	Control event rate - Treatment event rate (absolute risk reduction)
RRR	ARR / Control event rate (relative risk reduction)
Relative Risk (RR)	Risk in exposed / Risk in unexposed (used in cohort studies)
Odds Ratio (OR)	Odds in exposed / Odds in unexposed (used in case-control studies)
Hazard Ratio (HR)	Used in survival analyses with time-to-event endpoints

Confidence Intervals and P-values

95% CI: If CI for RR/OR includes 1.0, result is NOT statistically significant
95% CI for ARR: If CI includes 0, result is NOT statistically significant
P <0.05: Statistically significant, but NOT necessarily clinically meaningful
Type I error (alpha): False positive — finding an effect that does not exist
Type II error (beta): False negative — missing an effect that does exist
Power: 1 - beta; usually set at 80%; increased by larger sample size

Bias Types

Bias	Description
Selection bias	Non-random group allocation; threatens internal validity
Confounding	Third variable associated with both exposure and outcome
Recall bias	Retrospective studies; cases may recall exposures differently
Lead-time bias	Earlier detection makes survival appear longer without changing outcome
Publication bias	Positive results more likely published; detected by funnel plot asymmetry

Clinical Pearl: Always evaluate both statistical significance (p-value, CI) AND clinical significance (magnitude of effect, NNT/NNH) when interpreting trial results.

Study DesignsVolume 2

Types of clinical studies, levels of evidence, critical appraisal principles, and pharmacoeconomics for BCPS Domain 3.

Study Design Hierarchy

Design	Features	Strength
Systematic review / Meta-analysis	Pools multiple RCT data; quantitative synthesis	Highest (if RCTs)
RCT	Randomization controls confounding; prospective; blinding possible	High (causal inference)
Cohort study	Prospective or retrospective; follows groups over time; uses RR	Moderate
Case-control study	Retrospective; identifies cases vs controls; uses OR; efficient for rare outcomes	Moderate
Cross-sectional study	Snapshot in time; prevalence data; cannot establish causality	Lower
Case series / Case report	Descriptive; hypothesis-generating only	Lowest

Critical Appraisal Framework (PICO)

Population: Is the study population similar to my patient?
Intervention: Was the intervention clearly defined and applied consistently?
Comparison: Is the comparator appropriate (active control vs placebo)?
Outcome: Are the outcomes clinically meaningful (mortality vs surrogate)?

Pharmacoeconomic Study Types

Analysis Type	Outcome Measure	Result Reported As
Cost-minimization	Assumes equal effectiveness	Cost difference
Cost-effectiveness (CEA)	Natural units (lives saved, mmHg reduced)	Cost per outcome unit (ICER)
Cost-utility (CUA)	QALYs (quality-adjusted life years)	Cost per QALY; <$50-150k/QALY generally acceptable
Cost-benefit (CBA)	Monetary value assigned to outcomes	Net benefit or benefit-cost ratio

Surrogate vs Clinical Outcomes

Surrogate endpoints (HbA1c, LDL, BP) are easier to measure but may not always predict clinical benefit. Clinical (patient-centered) outcomes include mortality, hospitalizations, MI, stroke.

Clinical Pearl: Intention-to-treat (ITT) analysis preserves randomization and is most conservative; per-protocol analysis may overestimate treatment effect.

Healthcare SystemsVolume 2

Medication safety, quality improvement, formulary management, regulatory affairs, and healthcare policy.

Medication Error Types and Prevention

Error Type	Example	Prevention Strategy
Prescribing error	Wrong dose, wrong drug, omission	Clinical decision support, pharmacist review
Transcription error	Misread handwriting, wrong entry	CPOE, pharmacy verification
Dispensing error	Wrong drug or dose dispensed	Bar-code scanning, pharmacist counseling
Administration error	Wrong patient, wrong time, wrong route	5 rights, bar-code medication administration (BCMA)

High-Alert Medications (ISMP)

Insulin, heparin, concentrated electrolytes (KCl, hypertonic saline), opioids, chemotherapy, neuromuscular blockers, anticoagulants, antithrombotics.

Require independent double-checks, weight-based dosing protocols, and standardized concentrations.

Quality Improvement Methodologies

Method	Description
PDSA cycle	Plan-Do-Study-Act; rapid iterative testing of changes
Root Cause Analysis (RCA)	Retrospective after adverse event; identifies system failures
Failure Mode Effects Analysis (FMEA)	Proactive; identifies potential failure points before they occur
Lean / Six Sigma	Reduce waste / reduce variation in processes

Drug Approval Pathways (FDA)

Standard Review: Standard NDA/BLA; 10-12 months
Priority Review: Serious condition, significant improvement; 6 months
Breakthrough Therapy: Preliminary evidence of substantial improvement over existing therapy
Accelerated Approval: Based on surrogate endpoint; confirmatory trial required post-approval
Fast Track: Facilitates development for serious conditions

Clinical Pearl: Medication reconciliation at transitions of care (admission, discharge, transfer) is a critical patient safety step and a BCPS exam favorite for healthcare systems questions.

Oncology Supportive CareVolume 2

Chemotherapy-induced nausea/vomiting, myelosuppression, supportive medications, and oncologic emergencies.

CINV Prophylaxis by Emetogenic Risk

Risk Level	Regimen
High (e.g., cisplatin)	5-HT3 antagonist + NK1 antagonist (aprepitant) + dexamethasone ± olanzapine
Moderate (e.g., carboplatin)	5-HT3 antagonist + dexamethasone ± NK1 antagonist
Low	Dexamethasone or prochlorperazine
Minimal	No routine prophylaxis

5-HT3 Antagonists Comparison

Drug	Duration	Notes
Ondansetron	Short-acting	QTc prolongation; max 16mg IV; avoid in high-risk QT patients
Granisetron	Short-acting	Less QTc risk; patch formulation available
Palonosetron	Long-acting (half-life 40h)	Preferred for delayed CINV; no QTc concern

Neutropenia and G-CSF

Febrile neutropenia: ANC <500 + fever >38.3°C → broad-spectrum antibiotics within 1 hour (cefepime or pip-tazo empirically)
G-CSF prophylaxis: Indicated if febrile neutropenia risk >20% (high-risk regimen); also used if <10-20% with risk factors
Filgrastim (Neupogen): Daily SQ injection; start 24-72h after chemotherapy
Pegfilgrastim (Neulasta): Single dose per chemo cycle; avoid within 14 days of next chemotherapy

Bone Metastases / Hypercalcemia of Malignancy

Drug	Use
Zoledronic acid	Monthly IV; skeletal-related events prevention; monitor renal function and dental health (ONJ risk)
Denosumab	Monthly SQ; RANK-L inhibitor; preferred if renal impairment; monitor Ca/Mg (hypocalcemia)
IV bisphosphonates + IV fluids	Hypercalcemia of malignancy; normal saline hydration first, then zoledronic acid

Clinical Pearl: Tumor lysis syndrome prophylaxis with allopurinol (moderate risk) or rasburicase (high risk — caution in G6PD deficiency) for highly proliferative malignancies.

GastroenterologyVolume 2

GERD, peptic ulcer disease, IBD, IBS, constipation, diarrhea, and hepatic pharmacotherapy.

GERD / PUD Management

Drug Class	Examples	Key Points
PPIs (first-line)	Omeprazole, pantoprazole, lansoprazole	Take 30-60 min before first meal; interactions with clopidogrel (omeprazole>others)
H2 Receptor Antagonists	Famotidine, nizatidine	Tolerance develops with continuous use; famotidine safer (no CYP2C19 interaction)
H. pylori eradication	Triple therapy: PPI + clarithromycin + amoxicillin x 14 days	Quadruple therapy preferred if clarithromycin resistance common; confirm eradication 4+ weeks after treatment

IBD Pharmacotherapy

Drug	Indication	Monitoring
Mesalamine	UC induction and maintenance	Renal function; Crohn usually requires systemic therapy
Corticosteroids	IBD flares (short-term only)	Bone density, glucose, adrenal suppression; budesonide for local effect
Azathioprine / 6-MP	Maintenance; steroid-sparing	CBC, LFTs; TPMT testing before initiation (thiopurine metabolism); lymphoma risk
Infliximab / adalimumab	Moderate-severe CD and UC	TB screening, hepatitis B, vaccinations before starting

Constipation Management

Osmotic: Polyethylene glycol (PEG/Miralax) - first-line for chronic constipation; safe in pregnancy and elderly

Stimulant: Senna, bisacodyl - for faster relief; avoid long-term without evaluation

Secretagogues: Linaclotide, lubiprostone - for IBS-C or chronic idiopathic constipation

Diarrhea Management

Loperamide: First-line for non-infectious acute diarrhea; avoid in C. diff or bloody diarrhea
Rifaximin: Traveler's diarrhea, IBS-D, hepatic encephalopathy (non-systemic)
Bismuth subsalicylate: Traveler's diarrhea; avoid in children/adolescents with viral illness (Reye syndrome risk)

Clinical Pearl: PPIs are associated with C. diff, pneumonia, hypomagnesemia, and vitamin B12/iron malabsorption with long-term use. Use lowest effective dose and reassess regularly.

GeriatricsVolume 2

Pharmacotherapy in older adults: Beers criteria, polypharmacy, falls risk, dementia, and pain management.

Beers Criteria — High-Yield Drugs to Avoid in Elderly

Drug Category	Concern
First-generation antihistamines (diphenhydramine, hydroxyzine)	Anticholinergic; confusion, falls, urinary retention; strong Beers
Benzodiazepines (all)	Falls, fractures, cognitive impairment, paradoxical agitation
Non-benzodiazepine hypnotics (Z-drugs: zolpidem, eszopiclone)	Falls, fractures, cognitive impairment; avoid in elderly
TCAs (amitriptyline, imipramine)	Anticholinergic; orthostatic hypotension; cardiac conduction
NSAIDs	GI bleed, AKI, fluid retention, worsened HF; avoid unless no alternatives
Proton pump inhibitors (long-term)	Fractures, C. diff, hypomagnesemia; use sparingly
Meperidine	Normeperidine accumulation → seizures; avoid in elderly
Sliding-scale insulin monotherapy	Hypoglycemia risk; reactive rather than proactive; avoid alone

Dementia Pharmacotherapy

Drug	Indication	Notes
Donepezil, rivastigmine, galantamine	Mild-moderate Alzheimer disease	AChE inhibitors; GI side effects; bradycardia
Memantine	Moderate-severe Alzheimer disease	NMDA receptor antagonist; can combine with AChE inhibitor

Falls Risk — HIGH RISK Medications

Opioids, benzodiazepines, Z-drugs, antipsychotics, antihypertensives, diuretics, antidepressants (especially TCAs and SSRIs in elderly), anticonvulsants, and antihistamines.

Pain Management in Elderly

Acetaminophen: First-line for mild-moderate pain; max 2-3g/day in elderly or hepatic disease
NSAIDs: Avoid if possible; if needed, lowest dose, shortest duration, with PPI gastroprotection
Opioids: Start low, go slow; constipation prophylaxis always; avoid long-acting opioids in opioid-naive elderly
Tramadol: Avoid in elderly (Beers); lowers seizure threshold; serotonin syndrome risk

Clinical Pearl: The STOPP/START criteria complement Beers criteria for identifying inappropriate prescribing in elderly. START identifies drugs often underused in elderly (e.g., statins in ASCVD, bisphosphonates in osteoporosis).

PediatricsVolume 2

Pediatric pharmacotherapy principles, weight-based dosing, common pediatric conditions, and off-label use.

Pediatric Dosing Principles

Concept	Key Points
Weight-based dosing	mg/kg calculations; use actual body weight; verify against max adult dose
Age-based PK differences	Neonates: reduced renal/hepatic clearance, larger Vd for water-soluble drugs; infants: increased hepatic metabolism
BSA dosing	Used for chemotherapy; BSA (m²) = √[(height cm × weight kg)/3600]
Formulations	Prefer liquids/suspensions for children; verify concentration carefully

Otitis Media Treatment

Scenario	Treatment
Uncomplicated AOM ≥2 years	Amoxicillin 80-90 mg/kg/day divided BID x 5-7 days
Treatment failure or PCN allergy	Amoxicillin-clavulanate or cefdinir; or clindamycin for PCN allergy
Age <2 years with bilateral AOM	Always treat; 10 days

Fever and Pain Management

Drug	Dose	Notes
Acetaminophen	10-15 mg/kg q4-6h (max 75mg/kg/day)	Safest for all ages; first-line for fever/pain
Ibuprofen	5-10 mg/kg q6-8h (max 40mg/kg/day)	Not recommended <6 months; anti-inflammatory benefit

Pediatric Drug Contraindications / Safety

Aspirin: Avoid in children/adolescents with viral illness (Reye syndrome)
Fluoroquinolones: Generally avoided in children (cartilage concerns); exceptions for certain infections
Tetracyclines: Avoid in children <8 years (tooth discoloration, bone growth)
Codeine/tramadol: Contraindicated in children post-tonsillectomy/adenoidectomy (CYP2D6 ultra-rapid metabolizers; fatal respiratory depression)
Metoclopramide: Extrapyramidal reactions more common in pediatric patients

Neonatal Considerations

Neonatal sepsis empiric coverage: Ampicillin + gentamicin (covers GBS, Listeria, Gram-negatives)

Jaundice: Phototherapy for neonatal hyperbilirubinemia; exchange transfusion for severe cases

Clinical Pearl: Always double-check pediatric doses against maximum adult doses — mg/kg calculations in larger children can exceed adult doses.

Drug InformationVolume 2

Drug information resources, systematic literature searching, evidence grading, and application to practice.

Drug Information Resource Types

Type	Examples	Use Case
Tertiary (pre-appraised)	Lexicomp, Micromedex, Clinical Pharmacology, UpToDate	Quick answers; dosing, interactions, safety; starting point
Secondary (indexing)	PubMed, Embase, International Pharmaceutical Abstracts (IPA)	Searching primary literature; finding recent studies
Primary	Original research articles, clinical trials, case reports	Most current evidence; requires critical appraisal

Systematic Literature Searching (Modified Systematic Approach)

Define the question (PICO format)
Select appropriate databases (PubMed, Embase, Cochrane)
Identify search terms (MeSH headings + keywords)
Apply filters (date, study type, language)
Screen titles/abstracts then full-text articles
Critically appraise and synthesize evidence

Evidence Grading Systems

System	Key Feature
GRADE	Rates evidence quality (high/moderate/low/very low) AND strength of recommendation (strong/conditional)
USPSTF A-I	A-D + I grades; A/B = recommended services; D = recommend against; I = insufficient evidence

Drug Interaction Evaluation

Pharmacokinetic (PK) interactions: Absorption, distribution, metabolism (CYP450), elimination — change drug levels
Pharmacodynamic (PD) interactions: Additive or antagonistic effects without changing levels (e.g., two QTc-prolonging drugs)
Clinically significant interaction criteria: Severity, documentation quality, patient-specific risk factors, ability to monitor and manage

FDA MedWatch and Pharmacovigilance

Voluntary reporting for suspected adverse drug events; healthcare professionals encouraged to report; required for manufacturers. Post-marketing surveillance detects rare ADRs not found in clinical trials (underpowered for rare events).

Clinical Pearl: When using tertiary references, always note the publication date — drug information evolves and a tertiary reference may not reflect the most recent FDA labeling changes or guideline updates.

BCPS Learning Hub by AinaDara

Reset All Progress?